A Pipeline for Discovering Inhibitors of Wildtype Tau Seeded Aggregation

This study establishes a robust pipeline for tau aggregation inhibitor discovery, integrating wildtype tau relevance with mutant tau models. The addition of an iPSC-neuronal model will further enhance the physiological fidelity of the pipeline. The mechanisms of the successful compounds are currently being determined to understand their mode of action, and will progress toward lead optimisation and preclinical evaluation, advancing therapeutic development for AD and related tauopathies.